PFE - Pfizer Inc.
| Previous Close | 37.66 |
| Open | 37.45 |
| Bid | 37.39 x 800 |
| Ask | 37.40 x 28000 |
| Day's Range | 37.31 - 37.60 |
| 52 Week Range | 32.32 - 39.43 |
| Volume | 13,173,678 |
| Avg. Volume | 20,500,949 |
| Market Cap | 218.511B |
| Beta | 0.92 |
| PE Ratio (TTM) | 10.38 |
| EPS (TTM) | 3.60 |
| Earnings Date | Jul 31, 2018 |
| Forward Dividend & Yield | 1.36 (3.66%) |
| Ex-Dividend Date | 2018-08-02 |
| 1y Target Est | 39.80 |
- MarketWatch•6 hours ago
AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short'
AbbVie Inc. (ABBV) shares dropped 5.5% in heavy Thursday morning trade after short seller Citron Research described the company as "the next great drug short" in a tweet and said it planned to release reports about the company. The Citron tweet came the day after Food and Drug Administration Commissioner Scott Gottlieb put out a plan to encourage the development and uptake of lower-priced biosimilar drugs, accusing large drugmakers in a speech of stymying the competition. The short seller also predicted that AbbVie shares, which closed at $94.40 on Wednesday, would drop to $60.
- Zacks•6 hours ago
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
Motley Fool•8 hours agoBetter Buy: Novavax, Inc. vs. Pfizer
Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.
- Reuters•9 hours ago
Trump thanks Novartis, Pfizer for not raising drug prices
U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.
- Reuters•9 hours ago
Trump thanks Novartis, Pfizer for not raising drug prices
U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.
- The Wall Street Journal•20 hours ago
[$$] Novartis Won’t Raise U.S. Drug Prices This Year
Novartis AG won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said Wednesday, days after Pfizer Inc. took a similar step following criticism from President Donald Trump. In an interview, Novartis Chief Executive Vas Narasimhan said the company would evaluate its strategy for 2019 when it has more clarity on the pricing environment. Last week, Pfizer said it would defer some recent drug-price increases, reversing course after Mr. Trump criticized the company for its plans to raise the prices of more than 40 drugs.
- MarketWatch•yesterday
Pfizer, Eli Lilly non-opioid pain drug nears finish line
A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.
- TheStreet.com•yesterday
5 Big Biotech Stories to Watch
President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.
Reuters•yesterdayNovartis hints at 2018 outlook hike despite drug price freeze
Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.
- Reuters•yesterday
Pfizer-Lilly pain drug meets late-stage trial goals
The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.
- Reuters•yesterday
Pfizer-Lilly pain drug meets late-stage trial goals
An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.
- Benzinga•yesterday
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pfizer Inc. (NYSE: PFE ) stock was trading slightly ...
- Reuters•yesterday
Hikma raising injectable opioids output to help ease shortage at U.S. hospitals
London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients. Injectable opioid painkillers, which hospitals use to manage pain after operations and in terminal illness, have been in short supply for more than a year largely due to production problems at Pfizer, the biggest supplier of the drugs. Pfizer has said it is making progress on its recovery plan, but it estimates that the supply of some of its injectables will not be fully restored until later this year or in 2019.
- Reuters•yesterday
Novartis joins Pfizer in halting U.S. drug price hikes
Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.
- Business Wire•yesterday
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
- Bloomberg•2 days ago
Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.
- Bloomberg•2 days ago
Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.
- Zacks•2 days ago
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
- Investopedia•2 days ago
TD Ameritrade: Setting Time Target Best Way for Investors to Ignore Noise
Geopolitical tensions are rising, and trade disagreements are increasing, leaving investors confused as to how to react to the daily headlines emanating out of Washington and Wall Street. A better option, one advocated by TD Ameritrade's chief market strategist J.J. Kinahan, is to set a time target on the investments in a portfolio and stick to it. "A lot of people set price targets, but they don't do a good enough job setting a time target," said Kinahan in an interview with Investopedia.
- CNBC•2 days ago
Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered
Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies need to lower the prices they charge.
- Investopedia•2 days ago
How Johnson & Johnson Became A Household Name
New Brunswick, N.J.-based Johnson & Johnson (NYSE: JNJ) is probably most famous as the parent company of multiple household products that double as household names. If you’ve ever bandaged a wound, rinsed your mouth, applied lotion, sanitized your hands, battled a headache, substituted sugar or treated heartburn, chances are excellent that you did so courtesy of Johnson & Johnson’s research and development. To quote company Chairman and CEO Alex Gorsky, “approximately 70% of our sales come from products with the number one or number two global market share position.” Johnson & Johnson boasts no fewer than 275 subsidiary companies, up from 250 three years ago.
- CNBC•3 days ago
Increasing drug prices despite public scrutiny 'makes absolutely no sense,' says analyst
Some drug companies continue to raise prices, despite mounting public scrutiny and pressure from the president. Pfizer raised the price of more than 40 medications at the beginning of July. "The pharmaceutical industry is very much addicted to price inflation in terms of growth," said analyst Elliot Wilbur.
- American City Business Journals•3 days ago
Pfizer begins late-stage testing of Spark's hemophilia B gene therapy
The two companies, which said a licensing deal in 2014, have completed the transfer of the therapy's development from Spark to Pfizer.
- American City Business Journals•3 days ago
UAB researchers make big discovery on diabetes research
UAB researchers have made a significant discovery in diabetes research – one that could reduce the skyrocketing costs of treatment.
